IMMUTEP ORD
Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial
Late-stage biotechnology specialist Immutep (ASX: IMM) has achieved significant improvement in response rates compared to historical controls in a trial evaluating its first-line non-small cell lung cancer (NSCLC) treatment candidate. The assessment of eftilagimod alpha (efti) with Keytruda and chemotherapy has achieved high response rates in the multi-centre INSIGHT-003 trial, an investigator-initiated study conducted by […]
Immutep delivers strong survival results in efti-Keytruda head and neck cancer immunotherapy trial
Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase IIb trial to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). The study, which evaluated eftilagimod alfa (efti) in combination with anti-PD-1 therapy Keytruda (pembrolizumab) as first-line therapy for […]
Immutep’s efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials
Immutep (ASX: IMM) has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus Keytruda (pembrolizumab) for patients with soft tissue sarcoma (STS). Based on preliminary analysis of 21 patients available for primary endpoint assessment, the trial at Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in […]
Immutep reports strong results from efti-KEYTRUDA combination in carcinoma treatment
Clinical-stage biotechnology company Immutep (ASX: IMM) has released top-line results from a Phase IIb trial evaluating eftilagimod alfa (efti) in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a first-line treatment for recurrent and metastatic head and neck squamous cell carcinoma. The results showed that a combination of both drugs can lead to overall response rates […]